Semi-allogeneic human fibroblasts (Immune Cell Therapy)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameSemi-allogeneic human fibroblasts (Immune Cell Therapy)
Drug Alias NameFibroblasts Transfected With DNA From Autologous Tumor自体肿瘤衍生的DNA转染的半同种异体成纤维细胞疫苗semi-allogeneic human fibroblasts (MRC-5) transfected with DNA
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of PittsburghImmune Cell Therapy Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesImmune Cell Therapy Inc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A